Breaking News Instant updates and real-time market news.

IQV

Iqvia

$164.32 /

-0.21 (-0.13%)

07:14
10/20/20
10/20
07:14
10/20/20
07:14

Iqvia sees Q4 EPS $1.93 - $2.03, consensus $1.97

Sees Q4 revenue $3.04B-$3.19B, consensus $3.02B.

  • 20

    Oct

IQV Iqvia
$164.32 /

-0.21 (-0.13%)

07/27/20 Truist
SunTrust raises price targets on select late-stage CROs
07/23/20 Baird
Iqvia price target raised to $180 from $156 at Baird
07/23/20 Wells Fargo
Iqvia price target raised to $185 from $155 at Wells Fargo
07/23/20 FBN Securities
Veeva initiated with an Outperform at FBN Securities

TODAY'S FREE FLY STORIES

Hot Stocks
Splunk CEO sells 15.5K shares of common stock » 20:28
04/13/21
04/13
20:28
04/13/21
20:28
SPLK

Splunk

$147.69 /

+3.07 (+2.12%)

In a regulatory filing,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
SPLK Splunk
$147.69 /

+3.07 (+2.12%)

SPLK Splunk
$147.69 /

+3.07 (+2.12%)

04/08/21 BofA
Splunk reinstated with a Buy at BofA
04/08/21 BofA
Splunk reinstated with a Buy at BofA
04/05/21 Goldman Sachs
Splunk chief growth officer hire a 'significant positive,' says Goldman Sachs
03/15/21 Credit Suisse
Splunk assumed with an Outperform at Credit Suisse
SPLK Splunk
$147.69 /

+3.07 (+2.12%)

SPLK Splunk
$147.69 /

+3.07 (+2.12%)

SPLK Splunk
$147.69 /

+3.07 (+2.12%)

SPLK Splunk
$147.69 /

+3.07 (+2.12%)

Periodicals
KKR, Brookfield Asset Management mulling bid for Toshiba, Bloomberg reports  20:22
04/13/21
04/13
20:22
04/13/21
20:22
TOSBF

Toshiba, also use TOSYY

$44.83 /

+4.41 (+10.91%)

, TOSYY

Toshiba

$23.28 /

+2.43 (+11.65%)

, KKR

KKR

$52.04 /

+0.025 (+0.05%)

, BAM

Brookfield

$45.52 /

-0.44 (-0.96%)

 
ShowHide Related Items >><<
TOSYY Toshiba
$23.28 /

+2.43 (+11.65%)

KKR KKR
$52.04 /

+0.025 (+0.05%)

BAM Brookfield
$45.52 /

-0.44 (-0.96%)

TOSBF Toshiba, also use TOSYY
$44.83 /

+4.41 (+10.91%)

04/22/20 UBS
Toshiba downgraded to Neutral from Buy at UBS
TOSYY Toshiba
$23.28 /

+2.43 (+11.65%)

03/19/21 SMBC Nikko
Toshiba upgraded to Outperform from Neutral at SMBC Nikko
02/19/21 Citi
Toshiba resumed with a Neutral at Citi
04/22/20 UBS
Toshiba downgraded to Neutral from Buy at UBS
KKR KKR
$52.04 /

+0.025 (+0.05%)

04/09/21 DA Davidson
Box price target lowered to $22 from $25 at DA Davidson
04/09/21 William Blair
KKR investment 'strong vote of confidence' in Box, says William Blair
04/09/21 William Blair
KKR investment 'strong vote of confidence' in Box, says William Blair
04/07/21 Seaport Global
Seaport downgrades Sempra Energy to Neutral after 'good, not great' SIP deal
BAM Brookfield
$45.52 /

-0.44 (-0.96%)

04/09/21 Deutsche Bank
Brookfield price target raised to $45 from $43 at Deutsche Bank
04/01/21 Evercore ISI
Brookfield Property downgraded to In Line from Outperform at Evercore ISI
03/31/21
Fly Intel: Top five analyst downgrades
03/31/21 Credit Suisse
Brookfield downgraded to Neutral from Outperform at Credit Suisse
KKR KKR
$52.04 /

+0.025 (+0.05%)

BAM Brookfield
$45.52 /

-0.44 (-0.96%)

  • 11
    Nov
TOSBF Toshiba, also use TOSYY
$44.83 /

+4.41 (+10.91%)

TOSYY Toshiba
$23.28 /

+2.43 (+11.65%)

KKR KKR
$52.04 /

+0.025 (+0.05%)

BAM Brookfield
$45.52 /

-0.44 (-0.96%)

TOSYY Toshiba
$23.28 /

+2.43 (+11.65%)

KKR KKR
$52.04 /

+0.025 (+0.05%)

BAM Brookfield
$45.52 /

-0.44 (-0.96%)

Earnings
Steel Partners reports Q4 adjusted EBITDA $67.1M vs. $46.6M last year » 20:12
04/13/21
04/13
20:12
04/13/21
20:12
SPLP

Steel Partners

$14.35 /

+ (+0.00%)

Reports Q4 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
SPLP Steel Partners
$14.35 /

+ (+0.00%)

SPLP Steel Partners
$14.35 /

+ (+0.00%)

SPLP Steel Partners
$14.35 /

+ (+0.00%)

Initiation
Retail Opportunity reinstated with an Outperform at Baird » 20:06
04/13/21
04/13
20:06
04/13/21
20:06
ROIC

Retail Opportunity

$16.49 /

+0.085 (+0.52%)

Baird analyst Wesley…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ROIC Retail Opportunity
$16.49 /

+0.085 (+0.52%)

ROIC Retail Opportunity
$16.49 /

+0.085 (+0.52%)

02/24/21 DA Davidson
Retail Opportunity price target raised to $18 from $12 at DA Davidson
01/19/21 BofA
Retail Opportunity double-upgraded to Buy from Underperform at BofA
01/19/21 BofA
Retail Opportunity upgraded to Buy from Underperform at BofA
12/14/20 KeyBanc
Retail Opportunity downgraded to Sector Weight from Overweight at KeyBanc
ROIC Retail Opportunity
$16.49 /

+0.085 (+0.52%)

Initiation
RPT Realty reinstated with a Neutral at Baird » 20:06
04/13/21
04/13
20:06
04/13/21
20:06
RPT

RPT Realty

$11.83 /

+0.025 (+0.21%)

Baird analyst Wesley…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
RPT RPT Realty
$11.83 /

+0.025 (+0.21%)

RPT RPT Realty
$11.83 /

+0.025 (+0.21%)

01/13/21 Jefferies
Jefferies upgrades 'overlooked' RPT Realty to Buy
01/13/21 Jefferies
RPT Realty upgraded to Buy from Hold at Jefferies
12/21/20 JPMorgan
JPMorgan changes ratings in REIT, Real Estate Services sectors into 2021
12/21/20 JPMorgan
RPT Realty upgraded to Neutral from Underweight at JPMorgan
RPT RPT Realty
$11.83 /

+0.025 (+0.21%)

Initiation
Retail Properties of America reinstated with a Neutral at Baird » 20:04
04/13/21
04/13
20:04
04/13/21
20:04
RPAI

Retail Properties of America

$10.90 /

-0.005 (-0.05%)

Baird analyst Wesley…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
RPAI Retail Properties of America
$10.90 /

-0.005 (-0.05%)

RPAI Retail Properties of America
$10.90 /

-0.005 (-0.05%)

03/04/21
Fly Intel: Top five analyst downgrades
03/04/21 KeyBanc
Retail Properties of America downgraded to Sector Weight at KeyBanc
03/04/21 KeyBanc
Retail Properties downgraded to Sector Weight from Overweight at KeyBanc
12/15/20 Citi
Retail Properties of America price target raised to $9.50 from $7 at Citi
RPAI Retail Properties of America
$10.90 /

-0.005 (-0.05%)

Initiation
Regency Centers reinstated with a Neutral at Baird » 20:04
04/13/21
04/13
20:04
04/13/21
20:04
REG

Regency Centers

$59.24 /

+0.84 (+1.44%)

Baird analyst Wesley…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
REG Regency Centers
$59.24 /

+0.84 (+1.44%)

REG Regency Centers
$59.24 /

+0.84 (+1.44%)

03/31/21 Truist
Regency Centers price target raised to $57 from $50 at Truist
03/16/21 Wells Fargo
Regency Centers price target raised to $63 from $52 at Wells Fargo
03/04/21 Argus
Regency Centers downgraded to Hold from Buy at Argus
03/04/21 Argus
Regency Centers downgraded to Hold from Buy at Argus
REG Regency Centers
$59.24 /

+0.84 (+1.44%)

REG Regency Centers
$59.24 /

+0.84 (+1.44%)

Initiation
Kimco Realty reinstated with an Outperform at Baird » 20:02
04/13/21
04/13
20:02
04/13/21
20:02
KIM

Kimco Realty

$19.68 /

+0.22 (+1.13%)

Baird analyst Wesley…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
KIM Kimco Realty
$19.68 /

+0.22 (+1.13%)

KIM Kimco Realty
$19.68 /

+0.22 (+1.13%)

20:00 Today Baird
Kimco Realty reinstated with an Outperform at Baird
03/05/21 Truist
Kimco Realty price target raised to $20 from $18 at Truist
02/12/21 Mizuho
Kimco Realty price target raised to $20 from $17 at Mizuho
01/11/21 Mizuho
Kimco Realty upgraded to Buy from Neutral at Mizuho
KIM Kimco Realty
$19.68 /

+0.22 (+1.13%)

KIM Kimco Realty
$19.68 /

+0.22 (+1.13%)

Initiation
Weingarten Realty reinstated with an Outperform at Baird » 20:01
04/13/21
04/13
20:01
04/13/21
20:01
WRI

Weingarten Realty

$27.49 /

+0.38 (+1.40%)

Baird analyst Wesley…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
WRI Weingarten Realty
$27.49 /

+0.38 (+1.40%)

WRI Weingarten Realty
$27.49 /

+0.38 (+1.40%)

03/09/21 BTIG
Weingarten Realty price target raised to $28 from $25 at BTIG
03/05/21 Truist
Weingarten Realty price target raised to $28 from $24 at Truist
01/28/21 Scotiabank
Weingarten Realty upgraded to Outperform at Scotiabank on 'Sunbelt preference'
01/28/21 Scotiabank
Weingarten Realty upgraded to Outperform from Sector Perform at Scotiabank
WRI Weingarten Realty
$27.49 /

+0.38 (+1.40%)

Downgrade
FLSmidth double-downgraded to Sell from Buy at Goldman Sachs » 19:59
04/13/21
04/13
19:59
04/13/21
19:59
FLIDY

FLSmidth

$3.74 /

-0.11 (-2.86%)

Goldman Sachs analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
FLIDY FLSmidth
$3.74 /

-0.11 (-2.86%)

02/19/21 RBC Capital
FLSmidth price target lowered to DKK 255 from DKK 270 at RBC Capital
02/11/21 Morgan Stanley
FLSmidth price target lowered to DKK 190 from DKK 200 at Morgan Stanley
12/08/20 Nordea
FLSmidth upgraded to Buy from Hold at Nordea
12/07/20 JPMorgan
FLSmidth price target raised to DKK 245 from DKK 230 at JPMorgan
Initiation
Epiroc initiated with a Buy at Goldman Sachs » 19:55
04/13/21
04/13
19:55
04/13/21
19:55
EPOKY

Epiroc

$23.87 /

+0.06 (+0.25%)

Goldman Sachs analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
EPOKY Epiroc
$23.87 /

+0.06 (+0.25%)

EPOKY Epiroc
$23.87 /

+0.06 (+0.25%)

15:12 Today UBS
Epiroc price target raised to SEK 200 from SEK 159 at UBS
05:18 Today Pareto
Epiroc downgraded to Sell from Hold at Pareto
04/12/21 Societe Generale
Epiroc downgraded to Hold on valuation at Societe Generale
04/12/21 Societe Generale
Epiroc downgraded to Hold from Buy at Societe Generale
Initiation
Metso Outotec reinstated with a Neutral at Goldman Sachs » 19:53
04/13/21
04/13
19:53
04/13/21
19:53
OUKPY

Metso Outotec

$5.66 /

+0.04 (+0.71%)

Goldman Sachs analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
OUKPY Metso Outotec
$5.66 /

+0.04 (+0.71%)

04/12/21 Societe Generale
Metso Outotec price target raised to EUR 11 from EUR 8.40 at Societe Generale
02/19/21 Credit Suisse
Metso Outotec price target raised to EUR 10.50 from EUR 9.40 at Credit Suisse
02/17/21 UBS
Metso Outotec price target raised to EUR 10.4 from EUR 10 at UBS
02/17/21 Morgan Stanley
Metso Outotec price target raised to EUR 9.60 from EUR 9.30 at Morgan Stanley
Upgrade
JFrog upgraded to Hold from Sell at Summit Insights » 19:06
04/13/21
04/13
19:06
04/13/21
19:06
FROG

JFrog

$51.99 /

+0.68 (+1.33%)

Summit Insights analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
FROG JFrog
$51.99 /

+0.68 (+1.33%)

FROG JFrog
$51.99 /

+0.68 (+1.33%)

01/05/21 Piper Sandler
JFrog price target lowered to $65 from $76 at Piper Sandler
11/05/20 Stifel
JFrog reported 'strong first print as a public company,' says Stifel
10/26/20 Stifel
SAP news impact may be company-specific for software sector, says Stifel
10/12/20 JPMorgan
JFrog initiated with an Overweight at JPMorgan
FROG JFrog
$51.99 /

+0.68 (+1.33%)

  • 16
    Sep
FROG JFrog
$51.99 /

+0.68 (+1.33%)

FROG JFrog
$51.99 /

+0.68 (+1.33%)

FROG JFrog
$51.99 /

+0.68 (+1.33%)

Hot Stocks
Galectin says Phase 1 belapectin data published in JITC » 19:03
04/13/21
04/13
19:03
04/13/21
19:03
GALT

Galectin Therapeutics

$2.17 /

-0.105 (-4.62%)

Galectin Therapeutics…

Galectin Therapeutics announced that a paper published in the peer-reviewed Journal for ImmunoTherapy of Cancer, the highest ranked fully open access immunology journal, provides further clinical evidence that using belapectin, a potent galectin-3 inhibitor, in combination with pembrolizumab, a PD-1 inhibitor, significantly enhances tumor response to immunotherapy in patients with advanced metastatic melanoma and head and neck squamous cell carcinoma. The paper, titled "Enhancing Clinical and Immunological Effects of anti-PD-1 with Belapectin, a Galectin-3 Inhibitor" describes results from an ongoing Phase 1 clinical study, a collaboration between Galectin Therapeutics and Providence Cancer Institute in Portland, Oregon. Following the recent publication of positive preclinical results that showed the inhibition of galectin-3 in combination with an agonist anti-OX40 monoclonal antibody reprograms the tumor microenvironment to favor anti-tumor activity, the current study tests the clinical hypothesis that galectin-3 blockade with belapectin in combination with pembrolizumab enhances tumor response for patients with advanced MM or HNSCC. In the study, as previously disclosed, an objective response was observed in 50% of MM and 33% of HNSCC patients. This compares favorably to published response rates on pembrolizumab alone. The authors noted that the combination was associated with fewer immune-mediated adverse events than anticipated with pembrolizumab alone. In addition, the analysis of patients' tumor tissue revealed reduced monocytic myeloid-derived suppressor cells and increased effector memory T-cell activation in responders compared with non-responders. Also, an increased baseline expression of galectin-3 positive tumor cells correlated with clinical response.

ShowHide Related Items >><<
GALT Galectin Therapeutics
$2.17 /

-0.105 (-4.62%)

GALT Galectin Therapeutics
$2.17 /

-0.105 (-4.62%)

Earnings
Washington Federal reports Q2 EPS 56c, consensus 48c » 19:02
04/13/21
04/13
19:02
04/13/21
19:02
WAFD

Washington Federal

$30.81 /

-0.64 (-2.03%)

Reports Q2 NII $124.0M…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
WAFD Washington Federal
$30.81 /

-0.64 (-2.03%)

WAFD Washington Federal
$30.81 /

-0.64 (-2.03%)

WAFD Washington Federal
$30.81 /

-0.64 (-2.03%)

Hot Stocks
J&J pauses vaccinations in all COVID-19 vaccine clinical trials » 18:54
04/13/21
04/13
18:54
04/13/21
18:54
JNJ

Johnson & Johnson

$159.51 /

-2.075 (-1.28%)

In an updated statement,…

In an updated statement, Johnson & Johnson said that it has made the decision to proactively delay the rollout of its COVID-19 vaccine in Europe and pause vaccinations in all Janssen COVID-19 vaccine clinical trials while it updates guidance for investigators and participants. "We have been working closely with medical experts and health authorities, and we strongly support the open communication of this information to healthcare professionals and the public," the company said. Reference Link

ShowHide Related Items >><<
JNJ Johnson & Johnson
$159.51 /

-2.075 (-1.28%)

JNJ Johnson & Johnson
$159.51 /

-2.075 (-1.28%)

09:34 Today Goldman Sachs
J&J vaccine had numerical blood clot imbalance in trial, says Goldman Sachs
09:33 Today Morgan Stanley
Morgan Stanley says J&J news could improve 2022 outlook for mRNA vaccine makers
09:21 Today JPMorgan
Vaccine pause 'incremental negative' for J&J, says JPMorgan
08:15 Today Piper Sandler
Piper reiterates $208 target on Moderna after J&J Covid vaccine pause
JNJ Johnson & Johnson
$159.51 /

-2.075 (-1.28%)

JNJ Johnson & Johnson
$159.51 /

-2.075 (-1.28%)

JNJ Johnson & Johnson
$159.51 /

-2.075 (-1.28%)

JNJ Johnson & Johnson
$159.51 /

-2.075 (-1.28%)

Hot Stocks
Televisa, Univision agree to combine content, production assets » 18:40
04/13/21
04/13
18:40
04/13/21
18:40
TV

Televisa

$10.12 /

+0.09 (+0.90%)

, SFTBY

SoftBank

$46.60 /

+0.155 (+0.33%)

Televisa (TV) and…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SFTBY SoftBank
$46.60 /

+0.155 (+0.33%)

TV Televisa
$10.12 /

+0.09 (+0.90%)

03/17/21 BBVA
Televisa upgraded to Outperform from Market Perform at BBVA
12/15/20 Morgan Stanley
Televisa downgraded to Equal Weight following rally at Morgan Stanley
12/15/20 Morgan Stanley
Televisa downgraded to Equal Weight from Overweight at Morgan Stanley
05/12/20 Credit Suisse
Televisa upgraded to Outperform from Neutral at Credit Suisse
SFTBY SoftBank
$46.60 /

+0.155 (+0.33%)

03/11/21 Jefferies
SoftBank downgraded to Hold from Buy at Jefferies
03/10/21 Morgan Stanley
SoftBank resumed with an Equal Weight at Morgan Stanley
11/27/20 Citi
SoftBank price target raised to 11,000 yen from 10,200 yen at Citi
09/18/20 Northland
Combined Nvidia-ARM a long-term risk for AMD, Intel and Vicor, says Northland
TV Televisa
$10.12 /

+0.09 (+0.90%)

SFTBY SoftBank
$46.60 /

+0.155 (+0.33%)

SFTBY SoftBank
$46.60 /

+0.155 (+0.33%)

Periodicals
Televisa to combine content, production assets with Univision, Bloomberg says » 18:37
04/13/21
04/13
18:37
04/13/21
18:37
TV

Televisa

$10.12 /

+0.09 (+0.90%)

Televisa will receive $3B…

Televisa will receive $3B in cash and $1.5B in equity as part of the deal, according to Bloomberg.

ShowHide Related Items >><<
TV Televisa
$10.12 /

+0.09 (+0.90%)

03/17/21 BBVA
Televisa upgraded to Outperform from Market Perform at BBVA
12/15/20 Morgan Stanley
Televisa downgraded to Equal Weight following rally at Morgan Stanley
12/15/20 Morgan Stanley
Televisa downgraded to Equal Weight from Overweight at Morgan Stanley
05/12/20 Credit Suisse
Televisa upgraded to Outperform from Neutral at Credit Suisse
Upgrade
Glencore upgraded to Buy from Neutral at Goldman Sachs » 18:35
04/13/21
04/13
18:35
04/13/21
18:35
GLNCY

Glencore

$7.85 /

+0.03 (+0.38%)

Goldman Sachs analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
GLNCY Glencore
$7.85 /

+0.03 (+0.38%)

GLNCY Glencore
$7.85 /

+0.03 (+0.38%)

04/12/21 Deutsche Bank
Glencore price target raised to 400 GBp from 350 GBp at Deutsche Bank
03/24/21 Morgan Stanley
Glencore price target raised to 307 GBp from 274 GBp at Morgan Stanley
03/05/21 JPMorgan
Glencore price target raised to 360 GBp from 350 GBp at JPMorgan
03/04/21 UBS
Glencore price target raised to 330 GBp from 320 GBp at UBS
GLNCY Glencore
$7.85 /

+0.03 (+0.38%)

Periodicals
Judge says Juul must face new racketeering allegations, Bloomberg says » 18:24
04/13/21
04/13
18:24
04/13/21
18:24
MO

Altria Group

$51.16 /

-0.59 (-1.14%)

Juul Labs, which is 35%…

Juul Labs, which is 35% owned by Altria, will have to face new racketeering claims accusing the vaping company of deliberately targeting teenagers, as litigation centers on the individual founders and directors of the company, Bloomberg's Joel Rosenblatt reports. A federal judge in San Francisco said that most of the allegations brought by consumers, local governments, and school district against Juul and Altria under the Racketeer Influenced and Corrupt Organizations Act can proceed, the author notes. Reference Link

ShowHide Related Items >><<
MO Altria Group
$51.16 /

-0.59 (-1.14%)

MO Altria Group
$51.16 /

-0.59 (-1.14%)

03/26/21
Fly Intel: Top five analyst upgrades
03/26/21 Jefferies
Altria Group upgraded to Buy from Hold at Jefferies
03/19/21 Deutsche Bank
Altria Group price target raised to $54 from $52 at Deutsche Bank
03/16/21
Fly Intel: Top five analyst downgrades
MO Altria Group
$51.16 /

-0.59 (-1.14%)

MO Altria Group
$51.16 /

-0.59 (-1.14%)

MO Altria Group
$51.16 /

-0.59 (-1.14%)

MO Altria Group
$51.16 /

-0.59 (-1.14%)

Hot Stocks
New Gold reports Q1 gold equivalent production 96,026 ounces » 18:21
04/13/21
04/13
18:21
04/13/21
18:21
NGD

New Gold

$1.82 /

+ (+0.00%)

Reports Q1 gold…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
NGD New Gold
$1.82 /

+ (+0.00%)

NGD New Gold
$1.82 /

+ (+0.00%)

02/22/21 Canaccord
New Gold price target lowered to C$2.75 from C$3.75 at Canaccord
02/11/21 National Bank
New Gold price target lowered to C$4 from C$4.25 at National Bank
02/03/21 CIBC
New Gold downgraded to Neutral after mine fatality at CIBC
02/02/21 CIBC
New Gold downgraded to Neutral from Outperformer at CIBC
NGD New Gold
$1.82 /

+ (+0.00%)

On The Fly
Fly Intel: After-Hours Movers » 18:19
04/13/21
04/13
18:19
04/13/21
18:19
SAP

SAP

$134.51 /

+2.08 (+1.57%)

, FLXN

Flexion

$9.37 /

+1.05 (+12.62%)

, BRKR

Bruker

$68.97 /

+1.43 (+2.12%)

, TEAM

Atlassian

$242.24 /

+11.72 (+5.08%)

, PKI

PerkinElmer

$135.39 /

+2.695 (+2.03%)

, MRNA

Moderna

$149.63 /

+10.34 (+7.42%)

, SEAC

SeaChange

$1.38 /

-0.095 (-6.46%)

, SFIX

Stitch Fix

$49.46 /

-1.3 (-2.56%)

, STSA

Satsuma Pharmaceuticals

$5.44 /

+0.37 (+7.30%)

Check out this evening's…

ShowHide Related Items >><<
TEAM Atlassian
$242.24 /

+11.72 (+5.08%)

STSA Satsuma Pharmaceuticals
$5.44 /

+0.37 (+7.30%)

SFIX Stitch Fix
$49.46 /

-1.3 (-2.56%)

SEAC SeaChange
$1.38 /

-0.095 (-6.46%)

SAP SAP
$134.51 /

+2.08 (+1.57%)

PKI PerkinElmer
$135.39 /

+2.695 (+2.03%)

MRNA Moderna
$149.63 /

+10.34 (+7.42%)

FLXN Flexion
$9.37 /

+1.05 (+12.62%)

BRKR Bruker
$68.97 /

+1.43 (+2.12%)

SAP SAP
$134.51 /

+2.08 (+1.57%)

04/09/21 Societe Generale
SAP price target lowered to EUR 136 from EUR 138 at Societe Generale
03/25/21 Credit Suisse
SAP assumed with an Outperform at Credit Suisse
03/12/21 JMP Securities
Domo price target raised to $89 from $80 at JMP Securities
03/10/21 Craig-Hallum
Talend go-shop 'could spark interest,' says Craig-Hallum
FLXN Flexion
$9.37 /

+1.05 (+12.62%)

04/06/21 RBC Capital
Flexion transferred with an Outperform at RBC Capital
08/20/20 Goldman Sachs
Flexion initiated with a Neutral at Goldman Sachs
07/30/20 Oppenheimer
Flexion initiated with an Outperform at Oppenheimer
07/29/20
Fly Intel: Top five analyst initiations
BRKR Bruker
$68.97 /

+1.43 (+2.12%)

02/17/21 Stifel
Bruker price target raised to $65 from $48 at Stifel
02/17/21 Citi
Bruker price target raised to $65 from $57 at Citi
02/05/21 Wells Fargo
Bruker downgraded to Equal Weight with $55 target at Wells Fargo
02/05/21 Wells Fargo
Bruker downgraded to Equal Weight from Overweight at Wells Fargo
TEAM Atlassian
$242.24 /

+11.72 (+5.08%)

03/08/21 Morgan Stanley
Software industry rating raised to Attractive from In-Line at Morgan Stanley
03/03/21 Citi
Atlassian assumed with a Buy at Citi
01/29/21 DA Davidson
Atlassian price target raised to $275 from $235 at DA Davidson
01/29/21 BMO Capital
Atlassian price target raised to $260 from $235 at BMO Capital
PKI PerkinElmer
$135.39 /

+2.695 (+2.03%)

02/03/21 Citi
PerkinElmer price target raised to $155 from $150 at Citi
01/07/21 Piper Sandler
Oxford Immunotec downgraded to Neutral from Overweight at Piper Sandler
01/07/21 Wells Fargo
PerkinElmer upgraded to Overweight from Equal Weight at Wells Fargo
01/07/21 Wells Fargo
PerkinElmer upgraded to Overweight from Equal Weight at Wells Fargo
MRNA Moderna
$149.63 /

+10.34 (+7.42%)

09:33 Today Morgan Stanley
Morgan Stanley says J&J news could improve 2022 outlook for mRNA vaccine makers
08:15 Today Piper Sandler
Piper reiterates $208 target on Moderna after J&J Covid vaccine pause
04/07/21 Jefferies
Catalent pact with Moderna removes potential overhang, says Jefferies
03/15/21 Piper Sandler
Piper Sandler bullish on Moderna as first subject vaccinated in '1283 study
SEAC SeaChange
$1.38 /

-0.095 (-6.46%)

09/09/20 Lake Street
SeaChange price target lowered to $2 from $4 at Lake Street
SFIX Stitch Fix
$49.46 /

-1.3 (-2.56%)

04/05/21 Evercore ISI
Stitch Fix initiated with an Outperform at Evercore ISI
03/09/21
Fly Intel: Top five analyst downgrades
03/09/21 Canaccord
Stitch Fix price target lowered to $68 from $72 at Canaccord
03/09/21 KeyBanc
Stitch Fix price target lowered to $75 from $95 at KeyBanc
STSA Satsuma Pharmaceuticals
$5.44 /

+0.37 (+7.30%)

04/05/21 Mizuho
Satsuma Pharmaceuticals price target raised to $7 from $3.50 at Mizuho
03/02/21 Credit Suisse
Satsuma Pharmaceuticals upgraded to Neutral from Underperform at Credit Suisse
03/02/21 Credit Suisse
Satsuma upgraded to Neutral from Underperform at Credit Suisse
11/11/20 Mizuho
Satsuma Pharmaceuticals price target lowered to $3.50 from $4 at Mizuho
TEAM Atlassian
$242.24 /

+11.72 (+5.08%)

STSA Satsuma Pharmaceuticals
$5.44 /

+0.37 (+7.30%)

SFIX Stitch Fix
$49.46 /

-1.3 (-2.56%)

SEAC SeaChange
$1.38 /

-0.095 (-6.46%)

SAP SAP
$134.51 /

+2.08 (+1.57%)

PKI PerkinElmer
$135.39 /

+2.695 (+2.03%)

MRNA Moderna
$149.63 /

+10.34 (+7.42%)

FLXN Flexion
$9.37 /

+1.05 (+12.62%)

BRKR Bruker
$68.97 /

+1.43 (+2.12%)

  • 30
    Mar
  • 21
    Oct
  • 21
    May
  • 19
    May
SAP SAP
$134.51 /

+2.08 (+1.57%)

MRNA Moderna
$149.63 /

+10.34 (+7.42%)

TEAM Atlassian
$242.24 /

+11.72 (+5.08%)

SFIX Stitch Fix
$49.46 /

-1.3 (-2.56%)

SEAC SeaChange
$1.38 /

-0.095 (-6.46%)

SAP SAP
$134.51 /

+2.08 (+1.57%)

PKI PerkinElmer
$135.39 /

+2.695 (+2.03%)

MRNA Moderna
$149.63 /

+10.34 (+7.42%)

BRKR Bruker
$68.97 /

+1.43 (+2.12%)

TEAM Atlassian
$242.24 /

+11.72 (+5.08%)

STSA Satsuma Pharmaceuticals
$5.44 /

+0.37 (+7.30%)

SFIX Stitch Fix
$49.46 /

-1.3 (-2.56%)

SEAC SeaChange
$1.38 /

-0.095 (-6.46%)

SAP SAP
$134.51 /

+2.08 (+1.57%)

MRNA Moderna
$149.63 /

+10.34 (+7.42%)

Upgrade
South32 upgraded to Conviction Buy from Buy at Goldman Sachs » 17:57
04/13/21
04/13
17:57
04/13/21
17:57
SOUHY

South32

$10.96 /

-0.07 (-0.63%)

Goldman Sachs analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SOUHY South32
$10.96 /

-0.07 (-0.63%)

SOUHY South32
$10.96 /

-0.07 (-0.63%)

04/07/21 Barclays
South32 price target raised to 145 GBp from 130 GBp at Barclays
03/10/21 Deutsche Bank
South32 price target lowered to 190 GBp from 200 GBp at Deutsche Bank
02/08/21 Barclays
South32 price target raised to 130 GBp from 125 GBp at Barclays
11/24/20 Barclays
South32 downgraded to Underweight from Overweight at Barclays
Upgrade
Sandfire Resources upgraded to Buy from Neutral at Goldman Sachs » 17:54
04/13/21
04/13
17:54
04/13/21
17:54
SFRRF

Sandfire Resources

$4.14 /

-0.35 (-7.80%)

Goldman Sachs analyst…

Goldman Sachs analyst Paul Young upgraded Sandfire Resources to Buy from Neutral with a price target of A$7.6, up from A$5.8. The analyst is citing his higher copper price forecasts along with the company's "compelling valuation" at 0.72-times net asset value and 1.2-times expected EBITDA on next-12-month basis.

Hot Stocks
Stitch Fix slips 6.3% to about $46 after CEO transition » 17:52
04/13/21
04/13
17:52
04/13/21
17:52
SFIX

Stitch Fix

$49.46 /

-1.3 (-2.56%)

Shares of Stitch Fix…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SFIX Stitch Fix
$49.46 /

-1.3 (-2.56%)

SFIX Stitch Fix
$49.46 /

-1.3 (-2.56%)

04/05/21 Evercore ISI
Stitch Fix initiated with an Outperform at Evercore ISI
03/09/21
Fly Intel: Top five analyst downgrades
03/09/21 Canaccord
Stitch Fix price target lowered to $68 from $72 at Canaccord
03/09/21 KeyBanc
Stitch Fix price target lowered to $75 from $95 at KeyBanc
SFIX Stitch Fix
$49.46 /

-1.3 (-2.56%)

SFIX Stitch Fix
$49.46 /

-1.3 (-2.56%)

SFIX Stitch Fix
$49.46 /

-1.3 (-2.56%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.